迈向合理化肿瘤治疗:优化给药剂量、递送、排程与联合方案
本文综述了抗癌药物从传统细胞毒药物到最新免疫检查点抑制剂的药代动力学/药效学关系,指出标准剂量向个体化剂量转变有助于将药物暴露维持在治疗窗内,以确保疗效/毒性平衡最优。文章还讨论了导致长期被忽视的患者间变异的常见来源,以及通过治疗药物监测联合自适应给药策略或模型驱动的个体化给药与排程来实现肿瘤学真正个体化医疗的可行路径。
要点
- 抗癌药物个体化不仅在于选药,还在于优化给药剂量、递送、排程与联合方案。
- 从标准剂量转向个体化剂量有助于将药物暴露维持在治疗窗内,优化疗效/毒性平衡。
- 实现肿瘤个体化医疗可借助治疗药物监测联合自适应给药或模型驱动的给药与排程。
核心结论
- 在精心选择药物的基础上,进一步个体化给药模式(剂量、递送、排程与联合)可优化抗癌治疗的疗效/毒性平衡。
研究设计与样本
- 本文为综述,覆盖从数十年历史的细胞毒药物到最新免疫检查点抑制剂的抗癌药物药代动力学/药效学关系。
主要发现
- 从标准剂量转向个体化剂量应有助于将药物暴露水平维持在正确的治疗窗内,从而确保疗效/毒性平衡最优。
- 文章讨论了导致长期被忽视的患者间变异并影响药物暴露水平的最常见来源。
临床怎么用
- 可通过实施治疗药物监测联合自适应给药策略,或使用模型驱动的个体化给药与排程方式,推动肿瘤学真正个体化医疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The current trend to personalize anticancer therapies mostly relies on selecting the best drug or combination of drugs to achieve optimal efficacy in patients. In addition to the comprehensive genetic and molecular knowledge of each tumor before choosing the drugs to be given, there is probably much room left for improvement by further personalizing the very modes by which the drugs are given, once they have been carefully selected. In particular, shifting from standard dosing to tailored dosing should help in maintaining drug exposure levels in the right therapeutic window, thus ensuring that the efficacy/toxicity balance is optimal. This paper covers the current knowledge regarding pharmacokinetic/pharmacodynamic relationships of anticancer agents, from decades-old cytotoxics to the latest immune checkpoint inhibitors, the most frequent sources for long-neglected interpatient variability impacting on drug exposure levels, and what could be done to achieve real personalized medicine in oncology such as implementing therapeutic drug monitoring with adaptive dosing strategies or using model-driven modalities for personalized dosing and scheduling.
引用
- Ferrer F, Fanciullino R, Milano G, et al. Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations. Clin Pharmacol Ther. 2020. PMID: 32557660. doi:10.1002/cpt.1954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。